Results 71 to 80 of about 18,762 (211)

Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis [PDF]

, 2014
BACKGROUND: Accumulating evidence has shown that the inflammatory process participates in the pathogenesis of amyotrophic lateral sclerosis (ALS), suggesting a therapeutic potential of anti-inflammatory agents.
Akiko Namba, Choong Chi-Jing, Hideki Mochizuki, Hiroshi Shimagami, Hitoshi Kikutani, Josephe Archie Honorat, Kazushiro Takata, Saburo Sakoda, Satoru Tada, Tatsusada Okuno, Teruhito Yasui, Tomoyuki Sugimoto, Toru Koda, Yasumichi Hitoshi, Yuji Nakatsuji   +14 more
core   +1 more source

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

JEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni, Francois Rosset, Isotta Giunipero di Corteranzo, Lorenzo Bellando, Rebecca Senetta, Simone Ribero, Pietro Quaglino   +6 more
wiley   +1 more source

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. [PDF]

, 2015
ObjectiveTofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown.
Boyle, DL, Bradley, J, Firestein, GS, Hodge, J, Kaplan, I, Kavanaugh, A, Krishnaswami, S, Luo, Z, Mandel, D, Mease, P, Rosengren, S, Shurmur, R, Singhal, AK, Soma, K, Wei, N   +14 more
core  

Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis [PDF]

, 2015
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to joint destruction, disability, and decreased quality of life (QOL).
Akira Matsuo, Atsuo Tanimoto, Keisuke Nozawa, Mutsuyoshi Matsushita, Takayuki Yamaguchi, Wataru Amano, Yuichi Shinozaki, Yukari Kimoto   +7 more
core   +1 more source

REVEAL AD ‐ Prevalence of Moderate and Severe Atopic Dermatitis in Ireland: A Cross‐ Sectional, Real World Study of a Secondary Care Population

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a common inflammatory skin disease. However, limited data exist on its prevalence and incidence in Irish secondary care. Objectives REVEAL AD had two distinct but related objectives: (1) Estimate prevalence of moderate‐to‐severe AD in patients aged 12 years and older presenting to secondary care clinics in ...
Oisín S. Gough, Fiona McEvoy, Moneeb Saddiq, Michael O'Connell, Maeve Lynch, Brian Kirby, Michelle Murphy   +6 more
wiley   +1 more source

Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib

ACR Open Rheumatology, 2022
Objective Pain reduction with baricitinib was assessed in patients with rheumatoid arthritis (RA) who either used opioids or did not use opioids during three randomized, double‐blind phase 3 trials.
Janet E. Pope, Yvonne C. Lee, Jeffrey R. Curtis, Daojun Mo, Li Xie, Christina L. Dickson, Douglas E. Schlichting, Anabela Cardoso, Lee S. Simon, Peter C. Taylor   +9 more
doaj   +1 more source

SAR Studies on the Inhibitors for the Treatment of Inflammatory Diseases [PDF]

, 2016
School of Molecular Sciences(Chemistry)Inflammation is defensive host response that occurs from infection and injury and the inflammatory process is the pivotal physiological response of our body and essential part of the human physiology.
Kim, Min-Jeong
core  

Genome-wide inhibition of pro-atherogenic gene expression by multi-STAT targeting compounds as a novel treatment strategy of CVDs [PDF]

, 2018
Cardiovascular diseases (CVDs), including atherosclerosis, are globally the leading cause of death. Key factors contributing to onset and progression of atherosclerosis include the pro-inflammatory cytokines Interferon (IFN)a and IFN?
Bluyssen, Hans A.R., Collado, Aida, Marques, Patrice, Peiró, Concepción, Plens-Galaska, Martyna, Ramos-González, Mariella, Sanz, María Jesús, Szelag, Malgorzata, Vallejo, Susana, Wesoly, Joanna   +9 more
core   +3 more sources

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Baricitinib represses the myocardial fibrosis via blocking JAK/STAT and TGF-β1 pathways in vivo and in vitro

BMC Cardiovascular Disorders
Background JAK/STAT pathway is closely involved in the organ fibrotic process. The current study aimed to investigate the impact of baricitinib, an oral selective JAK1/JAK2 inhibitor, on the myocardial fibrosis in vivo and the activation of cardiac ...
Renlei Feng, Hongli Liu, Yunqing Chen
doaj   +1 more source